 |
 |
It has been found that the following four potassium channels are unique to the atrium (left figure), including IKur (ultra-rapidly-delayed rectifier K+ current), IKACh (acetylcholine-activated K+ current), IsKCa (Ca2+-activated small conductance K+ current) and IK2P (two pore domain K+ current). At present, these channels are considered as targets for the development of atrial selective anti atrial fibrillation drugs.
In recent years, several international pharmaceutical companies (e.g. Merck, Sanofi, Novartis, Xenion Ltd, etc.) have been committed to the development of atrial selective AF drugs, but they are still lacking in clinical practice. After more than 10 years of effort, we discovered that the natural small molecules inhibit three of the four potassium channels (i.e. IKur, IKACh and IsKCa).
Our products AMZ001 and AMZ002 can effectively prevent and terminate experimental atrial fibrillation in dogs. They belong to Class I atrial-selective anti-atrial fibrillation drugs. |
